Surveyed Endocrinologists and Rheumatologists Project Robust Uptake of Amgen/GlaxoSmithKline's Prolia for the Treatment of Osteo

However, Less Than A Quarter of Primary Care Physicians Are Familiar With Prolia, According to a New Report from Decision Resources

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that three quarters of surveyed endocrinologists and rheumatologists who are aware of Amgen/GlaxoSmithKline's Prolia anticipate prescribing the drug. However, according to Treatment Algorithms in Osteoporosis, while awareness of Prolia is good among specialists (94 percent of surveyed endocrinologists and 85 percent of surveyed rheumatologists are familiar with Prolia), primary care physicians (PCPs) report low awareness, with only 22 percent of surveyed PCPs saying they have heard of or are familiar with Prolia.

Prolia was approved for the treatment of osteoporosis in postmenopausal women at increased risk of fractures or patients who have failed or are intolerant to other osteoporosis treatment. As a result, specialists largely anticipate prescribing it as a second- or third-line treatment for osteoporosis. Surveyed endocrinologists anticipate just 17 percent of their prescriptions for Prolia will be for first-line therapy by 2012. Meanwhile, rheumatologists anticipate an even smaller percentage of Prolia prescriptions will be used in the first line -- they anticipate only 6 percent of their Prolia prescriptions will be first-line use by 2012.

"Both surveyed endocrinologists and rheumatologists view Prolia as most likely to replace both oral and intravenously delivered bisphosphonates, such as Novartis's Reclast, in their treatment of osteoporosis," said Decision Resources Analyst Matthew Scutcher, Ph.D. "Surveyed endocrinologists also believe Prolia will replace other osteoporosis drugs such as Eli Lilly's selective estrogen receptor modulator Evista."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS LifeLink's Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:


Decision Resources

Decision Resources, Inc.

Lisa Osgood

Christopher Comfort

781-993-2606

781-993-2597

[email protected]

[email protected]




SOURCE Decision Resources

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.